CASC3 and leukemia: To identify novel mechanisms of BTZ resistance, the human CCRF-CEM leukemia cell line and its BTZ-resistant sublines, i.e. CEM/BTZ7 (10-fold resistance), CEM/BTZ100 (140-fold resistance) and CEM/BTZ200 cells (170-fold resistance) [31, 43] were studied and analyzed in a multi-modality array-based analyses including comparative genomic hybridization (CGH), micro-RNA (miRNA) and gene expression (GEP) arrays.